NCT05511389

Brief Summary

Atrial fibrillation is the most common heart rhythm disorder (arrhythmia) worldwide. Nearly 40 million people are affected by atrial fibrillation worldwide, and this number is expected to increase by over 50% by 2050. Atrial fibrillation can cause strokes, heart attacks, heart failure, poor quality of life and even death. Almost half a million deaths worldwide are expected to be related to atrial fibrillation by 2050, and many billions of dollars are spent on atrial fibrillation related healthcare in North America every year. We believe health outcomes for patients with atrial fibrillation, and healthcare costs associated with treating atrial fibrillation could be improved by optimizing existing treatments for atrial fibrillation and maximizing the likelihood of restoring normal heart rhythm. This allows them to benefit from lower stroke risk, better heart function, fewer symptoms and increased quality of life. Restoring normal sinus rhythm earlier prevents atrial fibrillation from causing permanent structural damage to the heart that in turn, makes atrial fibrillation intractable. Furthermore, patients in whom initial attempts to control atrial fibrillation are unsuccessful frequently require more medications or invasive catheter ablation procedures which are costly and carry substantial risk. Electrical cardioversion is the main way physicians restore normal heart rhythm. In this procedure, the heart is "shocked" back into normal rhythm using two electrodes on the chest. Done correctly, this procedure is safe and effective. Many things are known about electrical cardioversion, for example, the best type and amount of electricity to use. What we don't know is the best position of the electrodes on the chest and whether applying direct, physical pressure to the electrodes makes cardioversion more successful. Our prior research suggests that improving positioning and applying pressure may improve cardioversion, but this finding needs to be verified with a rigorous, dedicated trial. This study will demonstrate whether front-to-back, or front-to-side placement of the electrodes is more effective for electrical cardioversion of atrial fibrillation. We will also demonstrate whether manually applying pressure to the electrodes makes cardioversion more effective. Should our trial demonstrate a benefit for these techniques, we expect them to be universally applied around the world. Because hundreds of thousands of cardioversions are done each year, even small increases in cardioversion success means thousands fewer patients progress to needing more medications or invasive procedures to manage their atrial fibrillation. We will study consenting adults presenting for non-urgent cardioversion of their atrial fibrillation. After explaining the study to participants and gaining their consent, we will randomly assign them to front-to-side or front-to-back electrode placement. Patients who remain in atrial fibrillation after the first shock will randomly receive either manual pressure or not. We will compare the success of cardioversion for front-side versus front-back electrode placement, and for manual pressure versus none. We will evaluate success by using electrocardiograms to assess for restoration of the heart rhythm back to normal. We hypothesize that anterolateral electrode positioning is superior to anteroposterior electrode positioning. We also hypothesize that manual pressure is effective relative to none, when applied in patients who have had one unsuccessful shock already.

Trial Health

77
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,500

participants targeted

Target at P75+ for not_applicable atrial-fibrillation

Timeline
14mo left

Started Feb 2023

Typical duration for not_applicable atrial-fibrillation

Geographic Reach
1 country

2 active sites

Status
recruiting

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Progress74%
Feb 2023Jul 2027

First Submitted

Initial submission to the registry

August 19, 2022

Completed
4 days until next milestone

First Posted

Study publicly available on registry

August 23, 2022

Completed
6 months until next milestone

Study Start

First participant enrolled

February 22, 2023

Completed
4.3 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2027

Expected
1 month until next milestone

Study Completion

Last participant's last visit for all outcomes

July 1, 2027

Last Updated

May 14, 2025

Status Verified

May 1, 2025

Enrollment Period

4.3 years

First QC Date

August 19, 2022

Last Update Submit

May 8, 2025

Conditions

Outcome Measures

Primary Outcomes (1)

  • First-shock cardioversion success

    Reversion to sinus rhythm (5 consecutive P waves within 5 seconds of shock)

    At time of intervention

Secondary Outcomes (2)

  • Cumulative cardioversion success for anterolateral versus anteroposterior placement afte

    At time of intervention

  • Second shock success for manual pressure versus none

    At time of intervention

Other Outcomes (4)

  • Descriptive analysis of techniques and results for third, unrandomized, clinician directed shock

    At time of intervention

  • First shock cardioversion success (subgroup analysis) by electrode position

    At time of intervention

  • Second shock cardioversion success by manual pressure versus none

    At time of intervention

  • +1 more other outcomes

Study Arms (2)

Anterolateral shock vector

ACTIVE COMPARATOR

Patients with electrodes placed on the chest to obtain an anterolateral (front-to-side placement; also known as anteroapical) shock vector. If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same.

Other: Anterolateral electrode positionOther: Manual pressure

Anteroposterior shock vector

ACTIVE COMPARATOR

Patients with electrodes placed on the chest to obtain an anteroposterior (front-to-back placement) shock vector. If first shock is unsuccessful, participants who proceed to a second shock will be randomized to manual pressure versus none but electrode placement will remain the same.

Other: Anteroposterior electrode positionOther: Manual pressure

Interventions

As described previously

Anterolateral shock vector

As described previously

Anteroposterior shock vector

Manual pressure applied to the anterior electrode

Anterolateral shock vectorAnteroposterior shock vector

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Consenting adult patients scheduled for non-emergent electrical cardioversion of Atrial Fibrillation or Flutter

You may not qualify if:

  • Insufficiently anticoagulation for cardioversion as per Canadian Cardiovascular Society guidelines or have not undergone trans-esophageal echocardiography to rule out left atrial thrombus
  • Anatomic contraindication to anterolateral or anteroposterior placement (e.g. skin conditions or wounds)

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

Hamilton Health Sciences

Hamilton, Ontario, L8L2X2, Canada

RECRUITING

St Joseph's Healthcare Hamilton

Hamilton, Ontario, L8N4A6, Canada

RECRUITING

MeSH Terms

Conditions

Atrial FibrillationAtrial Flutter

Condition Hierarchy (Ancestors)

Arrhythmias, CardiacHeart DiseasesCardiovascular DiseasesPathologic ProcessesPathological Conditions, Signs and Symptoms

Central Study Contacts

William McIntyre, MD

CONTACT

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Model Details: With a partial factorial randomization to manual pressure versus not (second intervention) if the first randomized attempt is unsuccessful at restoring normal heart rhythm
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Adult Cardiology Fellow

Study Record Dates

First Submitted

August 19, 2022

First Posted

August 23, 2022

Study Start

February 22, 2023

Primary Completion (Estimated)

June 1, 2027

Study Completion (Estimated)

July 1, 2027

Last Updated

May 14, 2025

Record last verified: 2025-05

Locations